[Tanshinone IIA protects against triptolide-induced liver injury via Nrf2/ARE activation]

Cui-wen Guan1, Jing Jin1, Jia Li1

  • 1School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.

Insights

Tanshinone IIA protects against triptolide-induced liver injury by reducing oxidative stress and inflammation. This protection is mediated through the activation of the Nrf2/ARE pathway, highlighting a potential therapeutic strategy for liver damage.

Area of Science:

  • Hepatology
  • Toxicology
  • Pharmacology

Background:

  • Triptolide (TP) is a compound known to induce acute liver injury.
  • Oxidative stress and inflammation are key mechanisms in TP-induced hepatotoxicity.
  • Tanshinone IIA (Tan) is a potential therapeutic agent with antioxidant properties.

Purpose of the Study:

  • To investigate the protective effects of Tanshinone IIA against triptolide-induced liver injury in mice.
  • To elucidate the underlying mechanisms, particularly the role of the Nrf2/ARE pathway.

Main Methods:

  • Acute liver injury was induced in mice using triptolide.
  • Biochemical markers (AST, ALT, LDH, GSH, MDA) and antioxidant enzyme activities (GSH-PX, SOD, CAT) were measured.
  • Histopathological analysis, Western blotting for Nrf2 translocation, and real-time PCR for ARE-driven genes (GCLC, NQO1, HO-1) were performed.

Main Results:

  • Tanshinone IIA pretreatment significantly reduced liver injury markers (AST, ALT, LDH) and inhibited oxidative stress (decreased MDA, restored GSH and antioxidant enzymes).
  • Histopathological examination showed attenuated liver damage in Tan-pretreated mice.
  • Tan treatment led to nuclear accumulation of Nrf2 and increased expression of Nrf2/ARE target genes (GCLC, NQO1, HO-1).

Conclusions:

  • Tanshinone IIA demonstrates significant hepatoprotective effects against triptolide-induced acute liver injury.
  • The protective mechanism involves the activation of the Nrf2/ARE signaling pathway, enhancing the cellular antioxidant defense system.
  • Tanshinone IIA represents a promising therapeutic candidate for managing drug-induced liver injury.